{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.8","upperLimit":"11.8","value":"9.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"}],"units":"Participants"}],"description":"Progression Free Survival is defined as the time from registration to the earliest date of documentation of disease progression or death. The distribution of time to progression will be estimated using the method of Kaplan-Meier.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive Akt inhibitor MK2206 PO once weekly for 4 weeks. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nAkt Inhibitor MK2206: 150 mg given PO","id":"OG000","title":"Treatment (Akt Inhibitor MK2206)"}],"paramType":"MEDIAN","populationDescription":"Two patients were deemed ineligible and were not included in this endpoint.","reportingStatus":"POSTED","timeFrame":"Time of study entry to progression or death, up to 3 years after registration","title":"Median Progression Free Survival","type":"SECONDARY","unitOfMeasure":"months"}